ImmunoChemistry Technologies (ICT), a Minnesota-based biotechnology company that supplies unique biochemical laboratory reagents and assay tests to medical researchers, has changed ownership. Now majority women-owned, ICT develops new products to help researchers discover new treatments and drugs for cancer and other diseases affecting both animals and humans.
Zyoxel has announced preliminary results from a testing by Sanofi on Zyoxel’s LiverChip...
Molecular Devices' next-generation SpectraMax MiniMax 300 imaging cytometer is designed to...
AMS Biotechnology has developed a custom phospho-specific antibody production service that is...
QIAGEN Announces Third Co-development Program for Companion Diagnostics Paired with Lilly’s Investigational Cancer CompoundsNovember 18, 2013 10:51 am | News | Comments
QIAGEN announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments.
The IP & Science business of Thomson Reuters and NuMedii have started an initiative to identify new treatments for areas of unmet medical need. How does the partnership propose to systematically identify new applications for existing drug compounds? Find out...
Abcam's new Alexa Fluor 405/568/750 conjugated secondary antibodies to its existing Alexa Fluor 488/555/594/647 conjugates. Extensively tested in Abcam’s labs, the Alexa Fluor range guarantees bright staining and low background. Learn more...
Bio-Rad Laboratories' TGX FastCast acrylamide andTGX Stain-Free FastCast acrylamide kits are designed to provide handcast gel users access to Bio-Rad’s TGX gel chemistry, previously available only in precast gels.
Personal Genome Diagnostics Inc. will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx’s expertise in next-generation sequencing (NGS)-based cancer biomarker discovery to MolecularMD’s capabilities in the development, validation and global delivery of cancer companion diagnostics. Read more...
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, is enabling cancer research with its latest next-generation sequencing (NGS) product, the xGen Acute Myeloid Leukemia Cancer Panel v1.0.
Elsevier today announced that Sanofi has implemented QUOSA’s literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralized repository of product-related scientific literature.
Fluxion Biosciences has launched its BioFlux Quattro high-throughput array system for physiologically relevant live cell analysis.
Corning Incorporated's Corning TransportoCells are designed to help accelerate a key step in the drug discovery and development process.
Earlier this month, MPI Research broke ground for a new preclinical imaging center, which will open in spring 2014 in Mattawan, Mich. How will this new facility help advance drug development? Scott Haller, director of the new molecular imaging center, explains.
Sartorius Stedim Biotech (SSB) and BD Diagnostics today announced a collaboration to develop, manufacture and market various ready-to-use, prefilled media products for microbiological applications in pharmaceutical, biotech and research laboratories. So what will this strategic collaboration specifically involve?
Molecular Devices' ScanLater western blot detection system combines western blot membrane detection with a multimode microplate reader platform, eliminating the need to acquire a separate dedicated western blot system.
Life Technologies Corporation has extended its collaborative agreement with Japanese firm DNAVEC Corporation to launch CytoTune-iPS 2.0 Sendai Reprogramming Kit, the next-generation research technology that enables the most efficient method to develop induced pluripotent stem (iPS) cells from human somatic cells.
Researchers from RayBiotech Inc., in collaboration with scientists from several universities and institutes, have identified five biomarkers present in patient serum which allow for the early detection of ovarian cancer. What technology did the researchers use to make this discovery? Find out...
The new Model 2304 Automated Protein Denaturation System is designed to automate protein stability determinations using chemical denaturation.
Waters Corporation introduced the Waters Acquity QDa detector, which is designed to bring high-quality, mass spectral data to chromatographic separations.
The CLARIOstar microplate reader from BMG Labtech is the latest evolution in microplate reader instrumentation.
Hurel Corporation (North Brunswick, N.J.), a leading developer of cell-based tissue constructs and microfluidic assay platforms, announced a new research grant program to spur innovation in the use of its cell-based models in pharmaceutical and industrial toxicological research. Learn more...
Trianni Inc., a Californian biotechnology company, launched its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates. Read more...
Molecular Devices (Sunnyvale, Calif.) today launched the EarlyTox cardiotoxicity kit, a fast, simple and reliable fluorescence-based kit for identifying cardiotoxicity of drug candidates early in the discovery process.
Horizon Discovery (Horizon) has entered into a non-exclusive license agreement with Harvard University to access intellectual property related to the commercialization of CRISPR gene-editing technology for research use. By adding CRISPR to its GENESIS precision gene-editing platform, Horizon can now offer researchers a toolbox capable of performing rapid functional genomics experiments.
LifeSensors, Inc., a biotech company developing cutting-edge technologies for studying the ubiquitin pathway, has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase (DUB) substrates. How do these substrates differ from other available deubiquitinase substrates?
Thermo Fisher Scientific introduces two additional systems designed to advance intact protein analysis and “quanfirmation.” The new technology will be displayed at the 12th HUPO World Congress at the Pacifico Yokohama in booth 51 from Sept. 14-18, 2013.
Olympus has introduced a 40x silicone oil microscope objective, its latest innovation in silicone immersion microscope optics. The new objective fills out the company’s full line of silicone oil optics, which already includes 30x and 60x objectives.
Teva Pharmaceutical Industries and Lonza Group announced that following a strategic review of the Teva-Lonza Joint Venture, the companies have decided to discontinue their collaboration for the development, manufacturing, and marketing of biosimilars.
- Page 1